Despite the biological plausibility of CYP2C19 functional polymorphisms as modulators of susceptibility to cancer, inconsistent findings have appeared in the literature; for example, CYP2C19 PMs have a high incidence of stomach cancer and lung cancer [14], but conversely have a low incidence of bladder cancer [13]. This evidence concerns the gene CYP2C19 and urinary bladder carcinoma.